

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Brilliant Violet 605(TM) anti-mouse Ly-6C

RRID:AB_2562352

Type: Antibody

Proper Citation

BioLegend Cat# 128035, RRID:AB_2562352

Antibody Information

URL: http://antibodyregistry.org/AB_2562352

Proper Citation: BioLegend Cat# 128035, RRID:AB_2562352

Target Antigen: Ly-6C

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-mouse Ly-6C

Description: This monoclonal targets Ly-6C

Target Organism: mouse

Clone ID: Clone HK1.4

Antibody ID: AB_2562352

Vendor: BioLegend

Catalog Number: 128035

Alternative Catalog Numbers: 128036

Record Creation Time: 20250819T235336+0000

Record Last Update: 20250820T064444+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-mouse Ly-6C.

No alerts have been found for Brilliant Violet 605(TM) anti-mouse Ly-6C.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 44 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Guo M, et al. (2026) Effects of Lycium barbarum polysaccharide on the activation of pathogenic CD4 + T cells in a mouse model of multiple sclerosis. Neural regeneration research, 21(6), 2563.

Mateus-Tique J, et al. (2026) Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth. Cancer cell, 44(3), 534.

Kirschstein E, et al. (2026) Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer. Cancer cell, 44(5), 1080.

Qian P, et al. (2026) Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis. Immunity, 59(7), 1964.

Kim HM, et al. (2026) Controlled-release nanoparticle of toll-like receptors-7/8 agonist enhances immune activation and inhibits gastric cancer in a preclinical mouse model. Cancer cell international, 26(1).

Ledwith AE, et al. (2026) Yeast β -glucan supplementation supports immunometabolic anti-tumor responses and reverses obesity-induced dysfunction via trained hematopoiesis. Cell reports, 45(7), 117648.

Wang H, et al. (2026) Regulation of neutrophil homeostasis by the TNFAIP8 family of polarity proteins. Cell reports, 45(7), 117694.

Duval F, et al. (2025) Trajectories of macrophage ontogeny and reprogramming in cancer. iScience, 28(5), 112498.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Cao Z, et al. (2025) Interferon- γ -stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer. Cell reports. Medicine, 6(3), 102017.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. *Cell reports*, 44(10), 116314.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Zhang M, et al. (2025) Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. *Cell host & microbe*, 33(6), 915.

Chaudhry H, et al. (2025) Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitors reduce vascular inflammation in vitro and in vivo. *British journal of pharmacology*.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8⁺ T cell responses and promotes antitumor T cell therapy. *Cell reports*, 43(2), 113712.

Hayes BH, et al. (2024) Chromosomal instability induced in cancer can enhance macrophage-initiated immune responses that include anti-tumor IgG. *eLife*, 12.

Folkert IW, et al. (2024) An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis. *The Journal of experimental medicine*, 221(10).

Ikeda N, et al. (2023) The early neutrophil-committed progenitors aberrantly differentiate into immunoregulatory monocytes during emergency myelopoiesis. *Cell reports*, 42(3), 112165.

Vennin C, et al. (2023) Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. *Cancer cell*, 41(6), 1170.

Salzmann M, et al. (2023) Staphylococcus aureus extracellular adherence protein (Eap) reduces immune cell phenotype in developing but not in established atherosclerotic lesions. *Biochimica et biophysica acta. Molecular basis of disease*, 1869(3), 166616.